- 17. Use of the F_V antibody construct according to claim 15 for lysis of cells expressing CD30 surface proteins.
- 18. A transformant, containing the expression vector according to claim 8.

REMARKS

A marked-up version of amended claims is included herewith in Appendix A and a clean copy of all pending claims is included in Appendix B.

It is requested that the examination and prosecution of this application proceed on the basis of these amended claims 1-18.

Respectfully submitted,

Marianne Fuierer

Registration No. 39,983 Attorney for Applicants

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
P. O. Box 14329
Research Triangle Park, NC 27709

Phone: (919) 419-9350 Fax: (919) 419-9354 Attorney File: 4121-135

APPENDIX A

In the Specification

Please insert on page 1, between the title of the application and the first paragraph, the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U. S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02589 filed August 2, 2000, which in turn claims priority of German Patent Application No. 199 37 264.0 filed August 6, 1999.

In the Claims

Please amend claims 1-12 and 14 to read as follows:

- 1. \underline{A} F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.
- 2. The F_v antibody construct according to claim 1, wherein the CD16 receptor is derived from NK cells.
- 3. The F_V antibody construct according to claim 1 [or 2], wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
- 4. The F_V antibody construct according to <u>claim 1</u> [any of claims 1 to 3], wherein one binding site is present each.
- 5. The F_V antibody construct according to claim 4, encoded by the expression vector pKTD16-30 (DEM 12960).
- 6. The F_V antibody construct according to claim 1 [any of claims 1 to 3], wherein two

binding sites are present for each.

- 7. An expression [Expression] vector, coding for the F_V antibody construct according to claim 1 [any of claims 1 to 6].
- 8. <u>The expression</u> [Expression] vector according to claim 7, which is [namely] pKID16-30 (DSM 12960).
- 9. <u>A transformant</u>, [Transformant,] containing the expression vector according to claim 7 [or 8].
- 10. A method of producing the Fv antibody construct according to claim 1 [any of claims 1 to 6], comprising culturing the transformant according to claim 9 under suitable conditions.
- 11. A kit [Kit] comprising:
 - (a) an F_V antibody construct according to the invention and/or
 - (b) an expression vector according to the invention, and
 - (c) common auxiliary substances, such as buffers, solvents, carriers, controls and markers,

wherein one or more representatives of the individual components may be present.

- 12. Use of the F_V antibody construct according to claim 1 [any of claims 1 to 6] for lysis of cells expressing CD30 surface proteins.
- 14. Use according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

APPENDIX B

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U. S.C. §371 and claims the priority of International Patent Application No. PCT/DE00/02589 filed August 2, 2000, which in turn claims priority of German Patent Application No. 199 37 264.0 filed August 6, 1999.

In the Claims

A F_V antibody construct having binding sites for an CDI6 receptor and a CD3O surface protein.

- 2. The F_v antibody construct according to claim 1, wherein the CD16 receptor is derived from NK cells.
- 3. The F_V antibody construct according to claim 1, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
- 4. The F_V antibody construct according to claim 1, wherein one binding site is present each.
- 5. The F_V antibody construct according to claim 4, encoded by the expression vector pKTDl6-30 (DEM 12960).
- 6. The F_V antibody construct according to claim 1, wherein two binding sites are present for each.
- 7. An expression vector, coding for the F_V antibody construct according to claim 1.
- 8. The expression vector according to claim 7, which is pKID16-30 (DSM 12960).
- 9. A transformant, containing the expression vector according to claim 7.
- 10. A method of producing the Fv antibody construct according to claim 1, comprising

culturing the transformant according to claim 9 under suitable conditions.

- 11. A kit comprising:
 - (a) an F_V antibody construct according to the invention and/or
 - (b) an expression vector according to the invention, and
 - (c) common auxiliary substances, such as buffers, solvents, carriers, controls and markers,

wherein one or more representatives of the individual components may be present.

- 12. Use of the F_V antibody construct according to claim 1 for lysis of cells expressing CD30 surface proteins.
- 13. Use according to claim 12, wherein the cells are tumor cells.
- 14. Use according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
- 15. The F_V antibody construct according to claim 2, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
- 16. An expression vector, coding for the F_V antibody construct according to claim 15.
- 17. Use of the F_V antibody construct according to claim 15 for lysis of cells expressing CD30 surface proteins.
- 18. A transformant, containing the expression vector according to claim 8.